Encefalite cronica di rasmussen: Risultati dello studio collaborativo LICE sui criteri di diagnosi e trattamento

Translated title of the contribution: Rasmussen encephalitis: Results of LICE collaborative study on the definition of diagnostic criteria and therapy

Research output: Contribution to journalArticle

Abstract

The aims of the study were a) to identify the early manifestations of RE that can prompt an early and reasonably secure diagnosis and an early targeted therapy; b) to evaluate the efficacy of different medical and surgical therapies; c) to verify the diagnostic value of GluR3 antibodies. We reviewed the clinical, MRI and EEG features present at the onset in twelve patients with istologically proven RE, and the response to medical and surgical treatment in 16 cases. Furthermore, we evaluated the presence of anti-GluR3 antibodies in 11 RE patients, and in a control group. Our data demonstrate that a) the association of partial seizures, with focal EEG and MRI changes allow a tentative diagnosis of RE 4-6 months from first symptoms. The diagnosis can be confirmed in 9-12 months by neurologic deterioration and worsening of the MRI picture; b) although surgical therapy remains inevitable in the most cases, medical therapies (including steroids, immunoglobuline, and plasma exchange) can produce significant, albeit transient, effects and should be considered in selected patients; c) the presence of anti-GluR3 antibodies cannot be considered a marker for diagnosis, as it is not able to distinguish between RE and other forms of epilepsy.

Original languageItalian
Pages (from-to)147-150
Number of pages4
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number118
Publication statusPublished - Oct 2002

Fingerprint

Encephalitis
Electroencephalography
Anti-Idiotypic Antibodies
Plasma Exchange
Therapeutics
Secondary Prevention
Nervous System
Epilepsy
Seizures
Steroids
Control Groups
Antibodies

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

@article{531f2e7723d0426aa657194c097bd06d,
title = "Encefalite cronica di rasmussen: Risultati dello studio collaborativo LICE sui criteri di diagnosi e trattamento",
abstract = "The aims of the study were a) to identify the early manifestations of RE that can prompt an early and reasonably secure diagnosis and an early targeted therapy; b) to evaluate the efficacy of different medical and surgical therapies; c) to verify the diagnostic value of GluR3 antibodies. We reviewed the clinical, MRI and EEG features present at the onset in twelve patients with istologically proven RE, and the response to medical and surgical treatment in 16 cases. Furthermore, we evaluated the presence of anti-GluR3 antibodies in 11 RE patients, and in a control group. Our data demonstrate that a) the association of partial seizures, with focal EEG and MRI changes allow a tentative diagnosis of RE 4-6 months from first symptoms. The diagnosis can be confirmed in 9-12 months by neurologic deterioration and worsening of the MRI picture; b) although surgical therapy remains inevitable in the most cases, medical therapies (including steroids, immunoglobuline, and plasma exchange) can produce significant, albeit transient, effects and should be considered in selected patients; c) the presence of anti-GluR3 antibodies cannot be considered a marker for diagnosis, as it is not able to distinguish between RE and other forms of epilepsy.",
keywords = "Early Diagnosis, Rasmussen Encephalitis, Treatment",
author = "T. Granata",
year = "2002",
month = "10",
language = "Italian",
pages = "147--150",
journal = "Bollettino - Lega Italiana contro l'Epilessia",
issn = "0394-560X",
publisher = "Lega Italiana contro l'Epilessia",
number = "118",

}

TY - JOUR

T1 - Encefalite cronica di rasmussen

T2 - Risultati dello studio collaborativo LICE sui criteri di diagnosi e trattamento

AU - Granata, T.

PY - 2002/10

Y1 - 2002/10

N2 - The aims of the study were a) to identify the early manifestations of RE that can prompt an early and reasonably secure diagnosis and an early targeted therapy; b) to evaluate the efficacy of different medical and surgical therapies; c) to verify the diagnostic value of GluR3 antibodies. We reviewed the clinical, MRI and EEG features present at the onset in twelve patients with istologically proven RE, and the response to medical and surgical treatment in 16 cases. Furthermore, we evaluated the presence of anti-GluR3 antibodies in 11 RE patients, and in a control group. Our data demonstrate that a) the association of partial seizures, with focal EEG and MRI changes allow a tentative diagnosis of RE 4-6 months from first symptoms. The diagnosis can be confirmed in 9-12 months by neurologic deterioration and worsening of the MRI picture; b) although surgical therapy remains inevitable in the most cases, medical therapies (including steroids, immunoglobuline, and plasma exchange) can produce significant, albeit transient, effects and should be considered in selected patients; c) the presence of anti-GluR3 antibodies cannot be considered a marker for diagnosis, as it is not able to distinguish between RE and other forms of epilepsy.

AB - The aims of the study were a) to identify the early manifestations of RE that can prompt an early and reasonably secure diagnosis and an early targeted therapy; b) to evaluate the efficacy of different medical and surgical therapies; c) to verify the diagnostic value of GluR3 antibodies. We reviewed the clinical, MRI and EEG features present at the onset in twelve patients with istologically proven RE, and the response to medical and surgical treatment in 16 cases. Furthermore, we evaluated the presence of anti-GluR3 antibodies in 11 RE patients, and in a control group. Our data demonstrate that a) the association of partial seizures, with focal EEG and MRI changes allow a tentative diagnosis of RE 4-6 months from first symptoms. The diagnosis can be confirmed in 9-12 months by neurologic deterioration and worsening of the MRI picture; b) although surgical therapy remains inevitable in the most cases, medical therapies (including steroids, immunoglobuline, and plasma exchange) can produce significant, albeit transient, effects and should be considered in selected patients; c) the presence of anti-GluR3 antibodies cannot be considered a marker for diagnosis, as it is not able to distinguish between RE and other forms of epilepsy.

KW - Early Diagnosis

KW - Rasmussen Encephalitis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0036820947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036820947&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0036820947

SP - 147

EP - 150

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 118

ER -